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OBJECTIVE—Receptor activity–modifying proteins (RAMPs) 1,
2, and 3 are unusual accessory proteins that dictate the binding
speciﬁcity of two G protein–coupled receptors involved in energy
homeostasis: calcitonin gene–related peptide (CGRP) and amylin
receptors. These proteins are expressed throughout the central
nervous system (CNS), including in the brain regions involved in
the regulation of energy homeostasis, but the signiﬁcance of CNS
RAMPs in the control of energy balance remains unknown.
RESEARCH DESIGN AND METHODS—To examine the func-
tional signiﬁcance of modulating neuronal RAMP1, we assessed
the effect of overexpressing human RAMP1 (hRAMP1) in the CNS
on body energy balance.
RESULTS—Nestin/hRAMP1 transgenic mice have a remarkably
decreased body weight associated with reduced fat mass and
circulating leptin levels. The transgenic mice exhibited higher
energy expenditure as indicated by increased oxygen consump-
tion, body temperature, and sympathetic tone subserving brown
adipose tissue (BAT). Consistent with this, the nestin/hRAMP1
transgenic mice had elevated BAT mRNA levels of peroxisome
proliferator–activated receptor g coactivator 1a and uncoupling
protein 1 and 3, and these changes can be reversed by chronic
blockade of sympathetic nervous system signaling. Furthermore,
metabolic response to amylin was enhanced in the nestin/hRAMP1
mice whereas the response to CGRP was blunted, possibly the
result of higher expression of CGRP in the CNS.
CONCLUSIONS—These data demonstrate that CNS RAMP1
plays a pivotal role in the regulation of energy homeostasis by
promoting energy expenditure. Diabetes 60:1063–1071, 2011
T
he discovery of receptor activity–modifying pro-
teins (RAMPs) was a hallmark in the conceptual
evolution of the G protein–coupled receptors.
Involvement of RAMPs extended the pharma-
cology and mechanism of function of these receptors from
a single seven-transmembrane protein to a receptor com-
plex with a speciﬁc chaperone (1,2). RAMPs (RAMP1,
RAMP2, and RAMP3) are small, single-pass integral
membrane proteins with a large extracellular N-terminal
domain and a small intracellular COOH-terminal domain
(3,4). RAMP1 interacts with calcitonin-like receptor (CLR)
to yield calcitonin gene–related peptide (CGRP) receptor
binding speciﬁcity (1,5). Association of CLR with RAMPs 2
or 3 yields receptors for adrenomedullin (1,5). On the
other hand, interaction of RAMP1, 2, or 3 with calcitonin
receptor (CTR) changes the ligand speciﬁcity from calci-
tonin to generate distinct receptors with high afﬁnity for
amylin (6,7). Of note, the expression level of RAMPs is
subject to regulation during physiological challenge, such
as pregnancy and hypoxia, and is altered in pathologi-
cal states, including cardiovascular disease, diabetes, and
sepsis (2,4).
A number of studies have shown that both amylin and
CGRP are involved in the control of food intake and me-
tabolism. Amylin and CGRP administered systemically, as
a single bolus or chronically, decreased food intake and
body weight in rodents (8–10). Amylin and CGRP also de-
creased food intake and caused weight loss following
single or chronic intracerebroventricular (ICV) admin-
istration (8,11,12). Conversely, treatment with selective
antagonists of the amylin receptor or CGRP receptor in-
creased food intake, body weight, and adiposity in rats
(13,14). The potency of ICV administration of amylin and
CGRP as compared with systemic administrations indi-
cates that the effects of amylin and CGRP on food intake
and body weight are mediated by the central nervous
system (CNS). Thus, amylin and CGRP, which are released
by peripheral tissues (pancreas and gastrointestinal tract,
respectively) in response to nutrient stimulus following
ingestion of food, may act as afferent signals to inform the
CNS about the status of nutrient availability and energy
reserves, thereby regulating energy balance.
Consistent with the effects of amylin and CGRP on food
intake and energy balance, RAMPs are expressed in several
brain regions including the hypothalamus and brainstem
nuclei involved in the regulation of energy homeostasis
(2,15,16). The distribution of CTR and CLR overlaps with
RAMP proteins, particularly RAMP1 and RAMP2 in several
brain nuclei (2). Of note, in the brain, amylin-induced c-fos
activation was found to codistribute with distinct RAMP1,
2, and 3 mRNA (17). However, the importance of CNS
RAMPs for energy balance is unknown.
Here, we used a mouse model that overexpresses the
human RAMP1 gene in the CNS to demonstrate that neu-
ronal RAMP1 is critically involved in the regulation of
energy homeostasis. We show that elevation of RAMP1 in
the CNS increases energy expenditure and modulates the
brain actions of amylin and CGRP.
RESEARCH DESIGN AND METHODS
All procedures were approved by the University of Iowa Animal Care and Use
Committee. Nestin-hRAMP1 transgenic mice were produced by mating Nestin-
cre mice with green ﬂuorescence protein (GFP)
ﬂox-hRAMP1 mice. Unless oth-
erwise indicated, we used 12- to 24-week-old Tg(RAMP1) line 28412/3 (18)
crossed with nestin-cre mice having a B6;129 mixed genetic background,
yielding mice with contributions from the B6, 129, and SJL genetic backgrounds.
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ORIGINAL ARTICLEFor some studies, we conﬁrmed the phenotype using Tg(RAMP1) line 28245/3,
and where indicated, nestin-cre was introduced by an intercross with mice
obtained from The Jackson Laboratory (stock 003771) in only the B6 genetic
background, yielding mice with contributions from only the B6 and SJL genetic
backgrounds. Genotype of the mice was determined by PCR as described
previously (18). Mice were housed in groups of 3–5 per cage and maintained on
12-h light-dark cycle with lights on at 6:00 A.M.. Room temperature was main-
tained at 22°C. Food and water were available ad libitum except when the mice
were fasted or had their food restricted as described below.
Body weight and food intake studies. Mice were weighed once a week for
several weeks. To measure food intake, mice were housed separately in regular
cages and allowed to acclimate for at least 3 days before beginning the
measurements of 24-h food intake. To assess the effect of fasting on the feeding
behavior, individually housed mice (12–16 weeks old) were fasted for 24 h.
Food was returned at the onset of the dark cycle. Food intake and body weight
were recorded 24 h after the food was returned.
Agroupof wild-type micehad their body weightspaired tothat of transgenic
mice by adjusting the daily food intake, beginning at weaning (4 weeks of age)
until the mice reached 12 weeks of age. Parallel groups of control and
transgenic mice were fed ad libitum.
TotesttheeffectofICVinjectionofamylinandCGRP,acannulawasimplanted
into the lateral cerebral ventricle as described previously (19). Mice were fasted
for 24 h before ICV injection of vehicle (saline, 2 ml) or 0.2 nmol of amylin
(Bachem, Torrance, CA) or CGRP (Sigma-Aldrich, St. Louis, MO). The dosage of
amylin and CGRP was chosen based on preliminary studies in wild-type mice.
Food was returned 1 h after the ICV injections, corresponding to the onset of the
dark cycle. Body weight and food intake were then recorded after 24 h.
Fat pad analysis. Magnetic resonance imaging was performed in anesthetized
mice as described previously (20). In addition, different fat depots including
gonadal fat, mesenteric fat, retroperitoneal fat, and BAT were dissected at
death and weighed.
To examine the adipocytes, mice were perfused with fresh saline, followed
by 4% paraformaldehyde (Electron Microscopy Sciences, Hatﬁeld, PA), and
retroperitoneal fat was dissected, postﬁxed in 4% paraformaldehyde at 4°C
overnight. Tissue blocks were sectioned (7 mm) on a sliding microtome,
mounted onto gelatin-coated slides, and stained with standard hematoxylin
and eosin method. Slides were visualized and pictures were obtained using
Olympus BX-51 light microscope (ESICO, Davenport, IA). Cell sizes were
analyzed using National Institutes of Health ImageJ software (http://rsbweb.
nih.gov). At least three slides from each animal were analyzed.
Measurements of O2 consumption, body temperature, and locomotor
activity. O2 consumption was measured in mice housed individually in regu-
lar cages with free access to food and water. Regular ﬁlter lids were replaced
with well-sealed ﬁlter lids. Room air drawn through each cage was dried by
passage through two successive columns of CaSO4 (Drierite, Arcos, Newark,
NJ) desiccant, then analyzed for O2 (model S-3A/II, AEI Technologies, Pitts-
burgh, PA) content.
Radiotelemetric measurement was used to record body temperature and
locomotor activity in conscious mice using TA10TA-F20 transmitter (Data
Sciences, St.Paul, MN) which was implanted in the peritoneal cavity under
anesthesia. After 7 days recovery, body temperature and locomotor activity
were collected continuously for 6 days and analyzed using Data Science
Dataquest software.
Sympatheticnervous system activity. We used direct multiﬁber recording to
measure baseline BAT sympathetic nerve activity as described previously (19).
Brieﬂy, mice were anesthetized by intraperitoneal injection of ketamine/
xylaxine cocktail and the nerve subserving interscapular BAT was isolated,
suspended to bipolar electrodes (Cooner Wire, Chatsworth, CA) and secured
with silicone gel (Kwik-Cast; World Precision Instruments, Sarasota, FL). An
average of three separate measurements during a 30-min recording period was
taken as baseline value for each animal.
Α b-adrenergic blocker, propranolol, was used to interrupt the sympathetic
nervous system signaling. For this, osmotic minipumps containing either ve-
hicle (saline) or propranolol (10 mg/kg/day) were implanted subcutaneously in
anesthetized mice. After 2 weeks, body weight was determined and mice killed
by CO2 asphyxiation. BAT was collected from each mouse, freeze-clamped,
and stored at 280°C.
RNA isolation and quantitative RT-PCR. Total RNA from various tissues
was extracted using the Trizol method (Invitrogen, Carlsbad, CA) and reverse
transcribed with oligo-dT and Multiscribe reverse transcriptase (Applied Bio-
systems, NJ) (18,20). RNA levels were measured by quantitative RT-PCR using
IQ SYBR Green Supermix kit (Bio-Rad Laboratories, Hercules, CA), and b-actin
was used as internal control. Primers are provided in Supplementary Table 1.
Western blotting. BAT proteins were extracted using lysis buffer, resolved
by 10% SDS-PAGE, and transferred to polyvinylidene ﬂuoride membranes,
which were incubated with UCP1 antibody (#sc-6528; Santa Cruz Bio-
technology, Santa Cruz, CA) or glyceraldehyde-3-phosphate dehydrogenase
antibody (#sc-20357; Santa Cruz Biotechnology) followed by horseradish
peroxidase–conjugated secondary antibodies. Blots were detected with en-
hanced chemiluminescence and measured using National Institutes of Health
ImageJ and reported relative to the signal from control mice.
Analytical procedures. The cerebrospinal ﬂuid was collected as described
previously (21). Plasma was obtained by centrifuging (5,000 rpm for 8 min) the
blood. Leptin was measured by an ELISA kit (Crystal Chem Inc., Downers
Grove, IL), and CGRP was measured using an EIA kit (Cayman Chemical
Company, Ann Arbor, MI).
Statistical analysis. Data are presented as means 6 SEM. Analysis of dif-
ference was performed using Student t test, one- or two-way ANOVA. When
ANOVA reached signiﬁcance, the Fisher test was used to compare the mean
values among the different levels of mice groups and treatments. A value of
P , 0.05 was considered to be signiﬁcant.
RESULTS
Genetic overexpression of RAMP1 in the CNS. To
examine the functional signiﬁcance of modulating neuronal
RAMP1, we assessed the effect of overexpressing human
RAMP1 (hRAMP1) in the CNS on body energy balance. The
strategy we used was to breed mice expressing GFP
ﬂox-
hRAMP1, in which an upstream GFP cDNA includes a
translational stop sequence and a polyadenylation signal
that prevents expression of hRAMP1, with mice expressing
cre under the control of the CNS-speciﬁc nestin promoter
(nestin/hRAMP1 mice) (18). In this way, hRAMP1 expres-
sion is dependent on Cre recombinase excision of GFP at
ﬂanking loxP sites. The success of this strategy is demon-
strated by the expression of hRAMP1 in the brain (hypo-
thalamus, brainstem, and cortex) but not in the peripheral
tissues such as the liver, skeletal muscle, and adipose tissue
(Fig. 1A). The levels of hRAMP1 and endogenous mouse
RAMP1 were measured by quantitative RT-PCR. The trans-
genic mice have about 1.5-fold overall elevation of total
RAMP1 mRNA in the brain. A similar elevation was mea-
sured in the hypothalamus and brainstem (Supplementary
Fig. 1). The elevation was due to the expression of hRAMP1,
as the levels of mouse RAMP1 mRNA in those tissues was
comparable between nestin/hRAMP1 mice and littermate
controls. Likewise, the hRAMP1 transgene was not detect-
able in peripheral tissues (liver, skeletal muscle, and white
adipose tissue) by quantitative RT-PCR, and the mouse
RAMP1 mRNA in these peripheral tissues was not altered.
Transgenic mice overexpressing RAMP1 in the CNS
have reduced body weight. To investigate the importance
of neuronal RAMP1 for body weight regulation, we moni-
tored the weight of nestin/hRAMP1 mice and littermate
controls. Body weight was comparable between non-
transgenic mice and single-transgenic mice containing only
the hRAMP1 or nestin-cre transgenes (data not shown).
Strikingly, nestin/hRAMP1 mice exhibited much lower body
weight compared with littermate controls (Fig. 1B–C). This
difference in body weight can be detected at birth with
nestin/hRAMP1 mice weighing about 17% less than the
controls (1.77 6 0.06 vs. 2.13 6 0.04 g, P , 0.05) and was
sustained at weaning (with transgenic mice weighing about
18% less than controls) (Fig. 1C) .A f t e r2 5w e e k s ,t r a n s g e n i c
mice tended to gain less weight (12 6 1g )t h a nc o n t r o l s
(14 6 1 g), but this was not statistically different. The dif-
ference in body weight was observed in both male and fe-
male mice (Supplementary Fig. 2). The nose-anus length of
nestin/hRAMP1 mice (9.27 6 0.10 cm) is slightly, but sig-
niﬁcantly (P , 0.05), reduced as compared with littermate
controls (9.84 6 0.08 cm), supporting a role for CNS RAMP1
in growth regulation.
The reduced body weight was maintained throughout
the life span. Compared with control littermates between
CNS RAMP1 AND ENERGY EXPENDITURE
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mice had 25% and 16% reduction in body weight, re-
spectively (n =7 8 –122). The lower body weight was still
present in several 3-year-old nestin/hRAMP1 mice (data
not shown). To ascertain that the lean phenotype is not the
result of a nonspeciﬁc effect of the transgene, we analyzed
the body weight of a second GFP
ﬂox-hRAMP1 transgenic
line. The body weight of nestin/hRAMP1 line 28245/3 was
19% lower compared with littermates (P , 0.05, n =8 –14).
Finally, the lower body weight phenotype was reproduced
in transgenic mice produced by crossing GFP
ﬂox-hRAMP1
line 28412/3 with two lines of nestin-cre mice (see RESEARCH
DESIGN AND METHODS). Together, these data indicate that
overexpression of hRAMP1 in the CNS leads to body weight
reduction irrespective of the genetic background and the
phenotype persists throughout the life span.
Reduced adiposity in mice overexpressing RAMP1 in
the CNS. Using MRI, we found that nestin/hRAMP1 mice
had signiﬁcant reduction in total fat mass, but not in total
lean mass (Fig. 2A–C). Expressed as percent of body
weight, total fat mass was signiﬁcantly (P = 0.02) lower in
transgenic mice (22.2 6 2.6%) as compared with controls
(29.8 6 2.3%). The reduction in fat mass was conﬁrmed by
weighing the fat pads (Supplementary Fig. 3). In addition,
adipocytes (obtained from retroperitoneal fat) of nestin/
hRAMP1 mice were approximately half the size of adipo-
cytes from control animals (Fig. 2D–E). Consistent with
the reduced fat mass, the plasma level of the adipocyte-
derived hormone leptin was signiﬁcantly reduced in the
nestin/hRAMP1 mice (Fig. 2F). These results indicate that
reduced adiposity accounts for the decreased body weight
of nestin/hRAMP1 mice.
To determine whether the decreased adiposity in the
transgenic mice was driven mainly by CNS hRAMP1 or just
the consequence of reduced body weight, we measured fat
mass in control mice that have their body weight matched
to that of transgenic mice (Supplementary Fig. 4). We
found that the decreased fat mass cannot be explained
entirely by the reduction in body weight, therefore, impli-
cating the overexpression of the transgene in the CNS.
Orexigenic proﬁle of hypothalamic neuropeptides
in mice overexpressing RAMP1 in the CNS. To test
whether alterations in the hypothalamic mechanisms that
regulate energy balance may account for the lower adi-
posity and subsequent leanness of nestin/hRAMP1 mice,
we analyzed the RNA levels of key hypothalamic neuro-
peptides involved in the control of energy homeostasis
(22,23). This analysis revealed unanticipated alterations in
the neuropeptide expression levels. Unexpectedly, the ex-
pression level of the anorexigenic proopiomelanocortin
(pomc) gene was signiﬁcantly reduced in the nestin/hRAMP1
mice (Supplementary Fig. 5A). The expression of another
anorexigenic gene, cocaine- and amphetamine-related tran-
script (cart), was lower in the nestin/hRAMP1 mice, but the
difference did not reach statistical signiﬁcance.
Similarly, the mRNA level of orexin, an orexigenic
peptide, was decreased in nestin/hRAMP1 mice. There was
no signiﬁcant alteration in the mRNA levels of melanin-
concentrating hormone (MCH). On the other hand, the
expression of neuropeptide y (NPY) gene npy was in-
creased in the nestin/hRAMP1 mice as compared with the
controls (Supplementary Figure 5B). Of note, the mRNA
level of agouti-related protein (agrp), another orexigenic
peptide expressed in NPY neurons, was not altered.
We also examined whether these changes in hypothalamic
g e n ee x p r e s s i o nw e r ed u et ot h et r a n s g e n e( h R A M P 1 )o r
a consequence of reduced body weight. We found that con-
trol mice with body weights matched to that of transgenic
FIG. 1. Nestin/hRAMP1 transgenic mice have reduced body weight. A: A representative PCR comparing the expression of human and mouse RAMP1
in various tissues between nestin/hRAMP1 transgenic (Tg) mice and wild-type controls (Con). Hyp, hypothalamus; Brstm, brainstem; Sk Mus,
skeletal muscle; Adip, white adipose tissue. B: A photograph of a nestin/hRAMP1 transgenic mouse and a wild-type control littermate. C: Growth
curve of nestin/hRAMP1 and control mice (n =1 2 –19 per group). (A high-quality color representation of this ﬁgure is available in the online issue.)
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orexin, and npy than the transgenic mice (Supplementary
Figure 5C and D).
Overexpression of RAMP1 in the CNS does not alter
feeding behavior. At 5 weeks of age, nestin/hRAMP1
mice had reduced food intake (Fig. 3A). However, at later
ages, 10 weeks and beyond, food intake was not different
in nestin/hRAMP1 mice as compared with littermate con-
trols (Fig. 3A). Thus, although reduced food consumption in
young nestin/hRAMP1 mice may contribute to the lower
body weight and adiposity, the similar food intake at later
ages indicates that food intake does not contribute to
maintaining the lean phenotype of the nestin/hRAMP1 mice.
To test whether challenging the mice may reveal dif-
ference in appetite control and feeding behavior, we fasted
12- to 16-week-old transgenic and littermate control mice
for 24 h and measured their food intake 24 h after the food
was returned. Overnight fasting caused similar weight loss
in transgenic mice (2.3 6 1.1 g) relative to controls (2.4 6
0.5 g, P = 0.4). Food intake after fasting was not different
between the transgenic and control mice (Fig. 3B), but the
transgenic mice gained signiﬁcantly less weight (Fig. 3C),
suggesting that in the transgenic animals ingested fuels are
not stored, but rather metabolized. This was conﬁrmed by
calculating the food intake relative to weight gain ratio
(indirect indicator of calories dissipated as heat) which
was signiﬁcantly increased in the nestin/hRAMP1 mice
(Fig. 3D) supporting the assumption that these mice have
increased metabolism.
Increase energy expenditure in mice overexpressing
RAMP1 in the CNS. Consistent with the increased metab-
olism, oxygen consumption, expressed as a function of either
body mass (Fig. 4A) or lean mass (Fig. 4B), was signiﬁcantly
higher during daytime and nighttime in the transgenic mice.
Furthermore, nestin/hRAMP1 mice had signiﬁcantly higher
body temperatures than control mice (Fig. 4B). Locomotor
activity tends to be lower in nestin/hRAMP1 mice, but it was
not signiﬁcantly different (P =0 . 1 2a n dP =0 . 2 4d u r i n gt h e
day and the night, respectively) (Fig. 4C).
In line with the elevated energy expenditure, nestin/
hRAMP1 mice exhibited signiﬁcant increase in the mRNA
levels of peroxisome proliferator–activated receptor g coac-
tivator 1a (PGC1a), uncoupling protein (UCP) 1 and UCP3,
but not UCP2, in BAT (Fig. 5A). Consistent with the in-
creased mRNA, BAT UCP1 protein was increased in the
nestin/hRAMP1 mice (Fig. 5B). In addition, nestin/hRAMP1
mice exhibited ;90% higher BAT sympathetic nerve ac-
tivity (Fig. 5C).
To determine whether the increase in sympathetic out-
ﬂow could explain the changes in BAT gene expression in
transgenic mice, we tested the effect of blocking the sym-
pathetic nervous system signaling by subcutaneous infusion
of propranolol, a b-adrenergic receptor antagonist, for
2 weeks. Transgenic mice treated with propranolol gained
FIG. 2. Reduced adiposity of nestin/hRAMP1 transgenic mice. A: Representative T1-weighted MRI showing a decrease in fat mass in nestin/hRAMP1
mice as compared with controls. Coronal (top panels) and axial abdominal (bottom panels) sections of wild-type and nestin/hRAMP1 mice are
shown. B and C: Comparison of total lean mass (B) and total fat mass (C) between wild-type and nestin/hRAMP1 mice. D and E: Smaller white
adipocyte (obtained from retroperitoneal fat) stained with hematoxylin and eosin (D) and size measured using square pixels (sp) (E). F: Lower
circulating levels of the adipocyte-derived hormone, leptin, in nestin/hRAMP1 mice. *P < 0.05 vs. controls; n =5 –18. (A high-quality color rep-
resentation of this ﬁgure is available in the online issue.)
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(Fig. 5D). In addition, chronic blockade of b-adrenergic
receptors reversed the increase in mRNA levels of BAT
PGC1a, UCP1, and UCP3 (Fig. 5E). These data indicate
that overexpression of hRAMP1 in the CNS triggers an
increase in sympathetic nerve outﬂow to thermogenic
brown adipocytes leading to an increase in energy ex-
penditure through changes in the expression of key BAT
genes.
Brain actions of amylin and CGRP are differentially
altered in mice overexpressing RAMP1 in the CNS.
Since RAMP1 is a common subunit for both amylin and
CGRP receptors (1,5,24), we tested whether neuronal
overexpression of hRAMP1 alters the physiological
responses to both of these peptides. In control mice, ICV
injection of amylin and CGRP decreased food intake and
body weight and promoted the burning of calories as in-
dicated by the increased food intake to weight gain ratio
(Fig. 6A–C). Surprisingly, the transgenic mice exhibited
contrasting responses to amylin and CGRP. The amylin-
induced weight loss and increase in food intake to weight
gain ratio was signiﬁcantly enhanced in the transgenic
animals (Fig. 6A–C). In contrast, exogenous CGRP had
a blunted effect on food intake and body weight and did
not further increase food intake to weight gain ratio in the
nestin/hRAMP1 mice (Fig. 6D–F). The increased sensitivity
to amylin demonstrates that RAMP1 is critical for neuronal
action of this hormone and may contribute to the in-
creased energy expenditure of the nestin/hRAMP1 mice.
Given that chronic activation of the CGRP receptor
can generate a self-sustaining feedback loop leading to
increased expression of CGRP (encoded by the calca gene)
FIG. 3. Food intake of nestin/hRAMP1 transgenic mice. A: Twenty-four-hour food intake of nestin/hRAMP1 transgenic (Tg) mice and littermate
controls (Con) at different ages. B–D: Effect of refeeding after 24-h fasting period in 12- to 16-week-old nestin/hRAMP1 transgenic and control
mice: food intake (B), body weight gain (C), and the ratio of food intake (FI) (g) to weight gain (WG) (g) (D). *P < 0.05 vs. controls; n =8 –20.
FIG. 4. Increased energy expenditure in nestin/hRAMP1 transgenic mice. Compared with littermate controls (Con), nestin/hRAMP1 transgenic
(Tg) mice have increased oxygen consumption (VO2, normalized to body mass [A] or total lean mass [B]) and body temperature (C) and a slight,
but not signiﬁcant, reduction in locomotor activity (D). *P < 0.05 vs. controls; n =8 –12.
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response to exogenous CGRP in the nestin/hRAMP1 mice
may be the result of increased endogenous CGRP expres-
sion in these animals. In line with our hypothesis, the nestin/
hRAMP1 mice exhibited signiﬁcantly higher levels of hy-
pothalamic CGRP mRNA (Fig. 6G) and cerebrospinal ﬂuid
CGRP protein (Fig. 6H). In contrast, there was no signiﬁ-
cant difference (P = 0.87) in the plasma CGRP between the
transgenic and control mice. Together with the increased
sensitivity to amylin, this increase in brain CGRP may play
a role in the increased metabolism and energy expenditure
of the nestin/hRAMP1 animals.
DISCUSSION
The present investigation revealed a novel and critical role
for CNS RAMPs in the control of energy homeostasis. We
show that genetic elevation of RAMP1 in the CNS lead to
a marked lean phenotype in mice owing to reduced adi-
posity. Food intake was reduced only in 5-week-old trans-
genic mice. In contrast, the transgenic mice exhibited
marked increase in energy expenditure associated with
elevated expression proﬁle of BAT genes that promote
thermogenesis. Importantly, even when normalized to lean
body mass, energy expenditure is still elevated in the trans-
genic animals. Furthermore, we describe a key role for the
sympathetic nervous system in mediating the reduction in
adiposity and the increase in BAT gene expression proﬁle.
Finally, in the transgenic mice we demonstrated enhanced
potency of central action of amylin whereas the action of
CGRP was blunted, possibly as the result of higher expres-
sion of CGRP in the CNS. To our knowledge, this is the ﬁrst
r e p o r tt od o c u m e n tar o l ef o rC N SR A M P 1i nt h er e g u l a t i o n
of energy homeostasis.
Our results indicate that one functional role of the CNS
RAMP1 is to modulate activity in peripheral organs that
are crucial for the maintenance of body energy balance.
Indeed, CNS RAMP1 appears to activate the pathways that
promote energy expenditure as indicated by the increased
PGC1a, UCP1, and UCP3 mRNA levels in BAT of nestin/
hRAMP1 transgenic mice. PGC-1a is thought to play a
pivotal role in the control of brown fat development and
function by regulating the mitochondrial and thermogenic
genes, including ucp1 (25). The critical role for UCP1 has
been revealed using a mouse model that lacks the ucp1
gene. These mice were found to be unable to maintain
body temperature during cold exposure (26). In addition,
at thermoneutrality the ucp1 null mice became obese and
have increased sensitivity to diet-induced obesity (27).
Importantly, we showed that chronic infusion of
b-adrenergic receptor antagonist reversed the elevated
gene expression level of these genes in BAT of nestin/
hRAMP1 mice, which was associated with increased weight
gain in these transgenic animals. These ﬁnding demonstrate
the key role of the sympathetic nervous system in mediat-
ing the increased thermogenesis in mice overexpressing
RAMP1 in the CNS. The sympathetic nervous system is
an important regulatory mechanism of metabolism and
FIG. 5. Energy expenditure–promoting pathways are enhanced in nestin/hRAMP1 transgenic mice. A: Compared with controls, nestin/hRAMP1
mice have elevated BAT mRNA levels, by quantitative RT-PCR, of PGC1a, UCP1, and UCP3, but not UCP2. B: Consistent with the mRNA levels,
UCP1 protein measured by Western blot was increased in the BAT of nestin/hRAMP1 mice. C: Increased sympathetic nerve activity (SNA) recorded
from the nerve subserving interscapular BAT. D and E: Continuous subcutaneous infusion of b-adrenergic receptor antagonist, propranolol (10
mg/kg/day for 2 weeks), accelerated the weight gain (D) and normalized the elevated expression levels of PGC1a, UCP1, and UCP3 in BAT (E)o f
transgenic mice. *P < 0.05 vs. controls, §P < 0.05 vs. Tg + vehicle, †P < 0.05 vs. Con + vehicle and Tg + propranolol; n =4 –12.
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a signiﬁcant role in disease states such as obesity (28,29).
The autonomic center in the brain receives afferent signals
about the status of body energy reserves leading to auto-
nomic and behavioral adaptations aimed at maintaining
body weight homeostasis (22,30). Brown adipocytes re-
ceive dedicated noradrenergic innervations, and a cen-
trally triggered increase in sympathetic trafﬁc lead to
alterations in thermogenic activity in BAT resulting in an
increase in energy expenditure (29,31). The elevated
sympathetic nerve trafﬁc to BAT in transgenic mice con-
ﬁrms the importance of the sympathetic nervous system in
the lean phenotype of these animals.
It is striking that nestin/hRAMP1 mice exhibited higher
energy expenditure and leanness in spite of the orexigenic
expression proﬁle of hypothalamic neuropeptides. How-
ever, such gene expression proﬁle is consistent with the
decreased circulating levels of leptin and may be the
consequence of counter-regulatory mechanisms triggered
by the reduced fat stores in the transgenic mice. Alterna-
tively, the increased expression of neuropeptides such as
NPY may contribute to the alterations in sympathetic
nerve trafﬁc and energy expenditure in the transgenic
mice as NPY has been shown to amplify norepinephrine
action and elicit sympathetic excitation (32,33).
The enhanced CNS amylin action in terms of weight
reducing effect and increase in food intake to weight gain
ratio combined with the increased CGRP levels are in line
with the reduced body weight and fat mass and increased
energy expenditure of the nestin/hRAMP1 transgenic mice.
Several reports have shown that systemic or central amylin
administration increase energy expenditure as assessed by
indirect calorimetry and body temperature (34–36). This is
corroborated by the ﬁnding that the reduction in body
weight and fat mass induced by amylin treatment was not
entirely explained by the reduction in caloric intake (37).
Our ﬁndings are also consistent with the essential role of
RAMPs as chaperones for both amylin and CGRP recep-
tors and the importance of central action of both amylin
and CGRP in the regulation of energy balance (1,5,24).
CTR and CLR appear to associate with RAMPs in the
endoplasmic reticulum and are cotrafﬁcked to the cell
FIG. 6. Effects of amylin and CGRP in nestin/hRAMP1 mice. A–C: Effect of ICV administration of amylin (0.2 nmol) on body weight, food intake,
and food intake (FI, g) to weight gain (WG, g) ratio in nestin/hRAMP1 mice (Tg) as compared with controls (Con). D–F: Effect of ICV adminis-
tration of CGRP (0.2 nmol) on body weight, food intake, and food intake to weight gain ratio in nestin/hRAMP1 transgenic mice as compared with
littermate controls. G and H: Increased hypothalamic CGRP mRNA levels (G), measured by quantitative RT-PCR, and CGRP levels in the cere-
brospinal ﬂuid (H) in nestin/hRAMP1 mice. *P < 0.05 vs. vehicle, †P < 0.05 vs. controls treated with amylin, §P < 0.05 vs. controls; n =4 –10.
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receptors for amylin and CGRP, respectively (2). In COS-7
cells, only RAMP1 or RAMP3 can generate an amylin re-
ceptor phenotype (6). However, there is still little known
about the formation of amylin and CGRP receptor com-
plexes in tissues and the contribution of the resulting
heterodimers to physiological actions of amylin and CGRP.
Our ﬁndings demonstrate that in the CNS, RAMP1 is im-
portant for amylin action. Our data also indicate the rele-
vance of RAMP1 for the expression and action of brain
CGRP.
The use of a mouse model in which hRAMP1 was
overexpressed throughout the CNS using a cre-inducible
transgenic approach may be viewed as a limitation to the
current study because this strategy does not allow the
identiﬁcation of a speciﬁc brain site that drives the phe-
notype. However, in mice, RAMP1 mRNA was found to be
widely distributed throughout the brain (38). In addition,
an increase in RAMP1 mRNA levels under various con-
ditions including hypertension, heart failure, and preg-
nancy has been reported (2). Another limitation of our
study relates to the fact that the nestin-cre strategy yields
transgene expression not only in the CNS but also in pe-
ripheral nervous system, which may have contributed to
the phenotype we describe in the transgenic mice.
Our study indicates that RAMP1 is a potential thera-
peutic target to modulate body energy balance. The fea-
sibility of modulating RAMP1 as a therapeutic target has
been established by the efﬁcacy of RAMP1 antagonism for
treating migraine (39,40). Amylin signaling in the brain has
recently emerged as a potential target for the treatment of
obesity (41,42). Therefore, a better understanding of the
complex mechanism of amylin and CGRP receptor sig-
naling and the precise role of each component in con-
trolling energy balance is critical to enhance the design of
novel and effective pharmacological therapies to reduce
metabolic disorders.
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